Skip to main content
    C

    Calidi Biotherapeutics Inc. (CLDI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.55
    -0.05 (-8.50%)

    Market Cap: $2.21M

    Last updated: Nov 17, 2026 at 4:24 PM ET

    Calidi Biotherapeutics Inc. (CLDI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Calidi Biotherapeutics (CLDI) has a market cap of $2.21M. It holds $3.95M more cash than debt, 178.25% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$2.21M
    Latest price (Nov 17, 2026)$0.55

    Key Dates

    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Price Statistics

    The stock is down 97.70% over 52 weeks and trades 39.56% below its 50-day average.

    Beta (1Y)2.55
    52-Week Change-97.70%
    1-Month Change-29.65%
    3-Month Change-60.07%
    6-Month Change-81.28%
    Total Return (1Y)-97.70%
    Total Return (3Y CAGR)-94.63%
    Total Return (5Y CAGR)-87.63%
    Max Drawdown (1Y)-97.76%
    Max Drawdown (3Y)-99.99%
    Sharpe Ratio (1Y)-3.48
    Correlation with SPY (1Y)0.32
    50-Day Average$0.91
    200-Day Average$3.50
    52-Week Range$0.59 to $24.80
    RSI (14 Days)27.5
    Average Volume (20 Days)45.06K

    Price chart

    Financial Position

    Current assets cover 1.27x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.27x
    Quick Ratio1.27x
    Debt / Equity0.00x
    Interest Coverage-105.59x

    Returns and Efficiency

    Return on equity is -979.34% and return on assets is -289.21% over the last 12 months.

    Return on Equity (ROE)-979.34%
    Return on Assets (ROA)-289.21%

    Scores

    CLDI has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$423.00K
    Operating Income-$17.15M
    Pretax Income-$15.96M
    Net Income-$15.97M
    EBITDA-$14.35M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 29.53% of the $5.52M in total assets.

    Cash and Equivalents$3.95M
    Total Debt$0
    Net Cash$3.95M
    Net Cash Per Share$1.59
    Working Capital$1.01M
    Shareholder Equity$1.63M
    Book Value Per Share$0.66
    Total Assets$5.52M
    Total Liabilities$3.89M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $91.00K of capital spending, operating cash flow left -$15.94M of free cash flow.

    Operating Cash Flow-$15.85M
    Capital Expenditures$91.00K
    Free Cash Flow-$15.94M
    FCF Per Share-$4.34
    Depreciation and Amortization$1.70M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    CLDI does not pay a dividend. Its free cash flow yield is -1168.32%.

    FCF Yield-1168.32%
    Buyback Yield-473.94%
    Shareholder Yield-473.94%

    Stock Splits

    The last split was a 1-for-16 reverse split on Jul 31, 2026.

    Last Split DateJul 31, 2026
    Split TypeReverse split
    Split Ratio1:16

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CLDI

    What is CLDI's market cap?

    Calidi Biotherapeutics has a market cap of $2.21M.

    How many shares of CLDI are outstanding?

    Calidi Biotherapeutics has 2.48M shares outstanding.

    Does CLDI pay a dividend?

    No. Calidi Biotherapeutics does not pay a dividend.

    How much debt does CLDI have?

    Calidi Biotherapeutics has $0 of total debt and $3.95M of cash and equivalents, a net cash position of $3.95M.